SCHEMBL25216132

SCHEMBL25216132

CC(C)(C)OC(=O)Nc1ccc(-c2ccc(F)c(F)c2)cc1N

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 1/20 0.54
▸ AAK1 Q2M2I8 7/20 0.51
▸ ABCB1 P08183 2/20 0.43
▸ ABCC1 P33527 2/20 0.43
▸ MAP4K4 O95819 1/20 0.43
▸ HDAC1 Q13547 3/20 0.42
▸ HDAC2 Q92769 3/20 0.42
▸ KIF11 P52732 2/20 0.40
▸ KCNQ4 P56696 1/20 0.39
▸ KCNQ5 Q9NR82 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30059279 0.89 CYP17A1 (0.54) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL197036 0.89 CYP17A1 (0.54) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL20163070 0.88 ABCB1 (0.56) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL5868853 0.86 AAK1 (0.51) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL3786645 0.86 AAK1 (0.53) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL5868895 0.86 AAK1 (0.48) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL30118376 0.86 AAK1 (0.48) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL5869075 0.85 AAK1 (0.52) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL24233399 0.85 AAK1 (0.52) CYP17A1AAK1ABCB1ABCC1MAP4K4
SCHEMBL5868802 0.85 ABCB1 (0.54) CYP17A1AAK1ABCB1ABCC1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 — — EP disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 CYP17A1 1294/4885AAK1 2510/4885ABCB1 2557/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 CYP17A1 657/4885AAK1 3018/4885ABCB1 2185/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 CYP17A1 657/4885AAK1 3018/4885ABCB1 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback